Todos Med Ltd (TOMDF)

[JoeForkeyBolo]

Biogen Controversy And The Spillover Effect: Actionable Insights

https://seekingalpha.com/article/4438096-biogen-controversy-and-the-spillover-effect-actionable-insights

Todos Medical is mentioned in this article on Alzheimer's treatments. Read the entire article for proper perspective on the excerpts below.

Newer Approaches to AD

For the last few decades, so many attempts have been put on amyloid beta, and more recently, tau. But unfortunately, the amyloid beta angle of attack, besides Biogen’s extremely controversial approval, has been a complete failure. There are many other more interesting theories on Alzheimer’s pathophysiology, and this should not be surprising given the apparent heterogeneity of the disease. For example, Todos Medical (OTCQB:TOMDF), a company with a serum Alzheimer’s diagnostic in development that very closely aligns with the gold standard of Alzheimer’s diagnosis, amyloid PET cSUVR, views Alzheimer’s as “cancer of neuronal cells that are incapable of completing cell division due to their post-mitotic nature,” where neurons are trying to, but mostly cannot undergo mitosis (cell division), and that this dysfunction is mirrored in peripheral lymphocytes. What is interesting is, despite the diagnostic’s excellent correlation with amyloid PET (r = -0.848), their view of the disease is not at all an amyloid beta-driven theory. This is certainly an interesting view, and could be part of the Alzheimer’s puzzle. Personally, I believe there is quite a strong case to be made for neuroinflammation, at least as part of the problem and a good target for solution, even if it's not a primary driver. Todos’ LymPro test is immune-cell based, measuring CD69 in peripheral blood lymphocytes as a marker of entering the cell cycle. An algorithm ties this to a score, diagnosing MCI, and this will provide an extra step before going to get a scan.

The Winners

Mentioned above, Todos Medical Ltd. is developing an Alzheimer’s diagnostic that is blood-based and measures the immune system rather than amyloid or tau. Thus, no cerebrospinal fluid or expensive, costly scan is needed, and this can be done as a proxy before going to get subsequent, confirmatory imaging. Additionally, the expansion of the AD market to Todos represents an outsized opportunity and a potential acceleration of business far more meaningful, relatively, than to an already mature company like Quest Diagnostics.